Skip to Content


Generic name: polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride and potassium chloride
Dosage form: powder, for solution
Drug class: Laxatives

Medically reviewed by Last updated on May 24, 2021.


Clenz-Lyte™ (Polyethylene Glycol 3350 and Electrolytes for Oral Solution) is a white powder in a 4 liter jug for reconstitution, containing 236 g polyethylene glycol 3350, 22.74 g sodium sulfate (anhydrous), 6.74 g sodium bicarbonate, 5.86 g sodium chloride and 2.97 g potassium chloride. When dissolved in water to a volume of 4 liters, Clenz-Lyte™ is an isosmotic solution, for oral administration, having a mildly salty taste. Clenz-Lyte™ is administered orally or via nasogastric tube as a gastrointestinal lavage.


Clenz-Lyte™ induces a diarrhea which rapidly cleanses the bowel, usually within four hours. The osmotic activity of polyethylene glycol 3350 and the electrolyte concentration result in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid or electrolyte balance.


Clenz-Lyte™ is indicated for bowel cleansing prior to colonoscopy and barium enema X-ray examination.


Clenz-Lyte™ is contraindicated in patients known to be hypersensitive to any of the components. Clenz-Lyte™ is contraindicated in patients with gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon or ileus.


No additional ingredients, e.g. flavorings, should be added to the solution. Clenz-Lyte™ should be used with caution in patients with severe ulcerative colitis.



Patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration should be observed during the administration of Clenz-Lyte™, especially if it is administered via nasogastric tube. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of Clenz-Lyte™.

Information for patients:

Clenz-Lyte™ produces a watery stool which cleanses the bowel before examination. Prepare the solution according to the instructions on the bottle. It is more palatable if chilled. For best results, no solid food should be consumed during the 3 to 4 hour period before drinking the solution, but in no case should solid foods be eaten within 2 hours of taking Clenz-Lyte™.

Drink 240 mL (8 oz.) every 10 minutes. Rapid drinking of each portion is better than drinking small amounts continuously. The first bowel movement should occur approximately one hour after the start of Clenz-Lyte™ administration. You may experience some abdominal bloating and distention before the bowels start to move. If severe discomfort or distention occur, stop drinking temporarily or drink each portion at longer intervals until these symptoms disappear. Continue drinking until the watery stool is clear and free of solid matter. This usually requires at least 3 liters and it is best to drink all of the solution. Any unused portion should be discarded.

Drug Interactions:

Oral medication administered within one hour of the start of administration of Clenz-Lyte™ may be flushed from the gastrointestinal tract and not absorbed.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Carcinogenic and reproductive studies with animals have not been performed.


Category C.

Animal reproduction studies have not been conducted with Clenz-Lyte™. It is also not known whether Clenz-Lyte™ can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Clenz-Lyte™ should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Safety and effectiveness in children have not been established.


Nausea, abdominal fullness and bloating are the most common adverse reactions (occurring in up to 50% of patients) to administration of Clenz-Lyte™. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.

Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and "butterfly-like" infiltrate on chest X-ray after vomiting and aspirating PEG.


The recommended dose for adults is 4 liters of Clenz-Lyte™ prior to gastrointestinal examination, as ingestion of this dose produces a satisfactory preparation in over 95% of patients. Ideally, the patient should fast for approximately three or four hours prior to Clenz-Lyte™ administration, but in no case should solid food be given for at least two hours before the solution is given.

Clenz-Lyte™ is usually administered orally, but may be given via nasogastric tube to patients who are unwilling or unable to drink the solution. Oral administration is at a rate of 240 mL (8 oz.) every 10 minutes, until the 4 liters are consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. Nasogastric tube administration is at the rate of 20 to 30 mL per minute (1.2 to 1.8 liters per hour). The first bowel movement should occur approximately one hour after the start of Clenz-Lyte™ administration.

Various regimens have been used. One method is to schedule patients for examination in midmorning or later, allowing the patients three hours for drinking and an additional one hour period for complete bowel evacuation. Another method is to administer Clenz-Lyte™ on the evening before the examination, particularly if the patient is to have a barium enema.

Preparation of the solution:

Clenz-Lyte™ is prepared by filling the container to the 4 liter mark with water and shaking vigorously several times to ensure that the ingredients are dissolved. Dissolution is facilitated by using lukewarm water. The solution is more palatable if chilled before administration. The reconstituted solution should be refrigerated and used within 48 hours. Discard any unused portion.


In powdered form (white powder) for oral administration as a solution following reconstitution.

Clenz-Lyte™ is available in a disposable jug containing: polyethylene glycol 3350 236 g, sodium sulfate (anhydrous) 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, potassium chloride 2.97 g. When made up to 4 liters volume with water, the solution contains PEG-3350 17.6 mmol/L, sodium 125 mmol/L, sulfate 40 mmol/L, chloride 35 mmol/L, bicarbonate 20 mmol/L and potassium 10 mmol/L.


Store in sealed container at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.

NDC 0574-0427-04

Paddock Laboratories, Inc.
Minneapolis, MN 55427

Pat. 4488922


Polyethylene Glycol 3350 and Electrolytes for Oral Solution


  1. Add lukewarm drinking water to the fill mark (4 liters) on the bottle. Do not add any other ingredients, flavors, etc.
  2. Cap bottle securely and shake vigorously several times to ensure that the ingredients are dissolved.
  3. For best results, no solid food should be consumed for the 3 to 4 hour period before drinking the solution, but in no case should solid food be eaten within two hours of taking Clenz-Lyte™.
  4. Drink one 8 ounce (240 mL) cup of the solution rapidly every 10 minutes. A loose watery bowel movement should result in approximately one hour. Continue drinking until the entire contents (4 liters) have been consumed or as directed by a physician.

NOTE: The solution is more palatable if chilled in the refrigerator before drinking. Keep reconstituted solution refrigerated. Use within 48 hours. Discard unused portion.

NDC 0574-0427-04

Paddock Laboratories, Inc.
Minneapolis, MN 55427



Polyethylene Glycol 3350 and
Electrolytes for Oral Solution

NDC 0574-0427-04


TO PHARMACIST AND PATIENT: Mixing information is on base
label. Package insert may be removed before dispensing.

When reconstituted with water to a volume of 4 liters,
this solution contains 125 mmol/L sodium, 10 mmol/L
potassium, 40 mmol/L sulfate, 20 mmol/L bicarbonate,
35 mmol/L chloride, and 17.6 mmol/L polyethylene
glycol 3350.


Laboratories, Inc.

polyethylene glycol 3350 powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0574-0427
Route of Administration ORAL, NASOGASTRIC DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Polyethylene Glycol 3350 (Polyethylene Glycol 3350) Polyethylene Glycol 3350 236 g in 4 L
Sodium Sulfate Anhydrous (Sodium Cation) Sodium Sulfate Anhydrous 22.74 g in 4 L
Sodium Bicarbonate (Sodium Cation) Sodium Bicarbonate 6.74 g in 4 L
Sodium Chloride (Sodium Cation) Sodium Chloride 5.86 g in 4 L
Potassium Chloride (Potassium Cation) Potassium Chloride 2.97 g in 4 L
Product Characteristics
Color WHITE Score
Shape Size
Flavor Imprint Code
# Item Code Package Description
1 NDC:0574-0427-04 4 L in 1 JUG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA090769 06/07/2010
Labeler - Paddock Laboratories, Inc. (086116803)
Name Address ID/FEI Operations
Paddock Laboratories, Inc. 086116803 Manufacture
Paddock Laboratories, Inc.

More about Clenz-Lyte (polyethylene glycol 3350 with electrolytes)

Consumer resources

Professional resources

Other brands
GoLYTELY, Plenvu, MoviPrep, NuLYTELY, ... +6 more

Related treatment guides